Doctor Owen McMaster has more than 30 years’ experience helping to create nonclinical and regulatory strategies for developing drug products at the FDA. He is currently a Master Pharmacologist in FDA’s Center for Drug Evaluation and Research with experience working with multiple technical subcommittees and the Education subcommittee of the Pharmacology Toxicology Coordinating Committee. He provides nonclinical and regulatory strategic advice to biopharmaceutical companies seeking to advance complex development programs for therapeutics intended to treat a wide variety of diseases under IND and NDA marketing applications. Across his career he has served as a thought leader on the assessment communication and management of risks related to various types of products including small molecules and biologics. His background in Biochemical Pharmacology and Neuropharmacology has allowed him to speak at international meetings on topics that include use of drugs with abuse potential such as cannabinoids.